间充质干细胞
临床试验
再生医学
医学
移植
重症监护医学
干细胞
再生(生物学)
细胞疗法
生物信息学
生物
病理
内科学
遗传学
细胞生物学
作者
Yiling Si,Yali Zhao,Hao-jie Hao,Xiaobing Fu,Weidong Han
标识
DOI:10.1016/j.arr.2010.08.005
摘要
Mesenchymal stem cells (MSCs) are multi-potent adult stem cells harboring multi-lineage differentiation potential and immunosuppressive properties that make MSCs an ideal candidate cell type for immunomodulation and regenerative medicine. Currently, MSC-related researches and clinical trials have evoked exciting promise in a variety of disorders and tissue regeneration. However, it must be recognized that several critical potential problems have also emerged from current clinical trials, for example: (1) the indefinite association between the phenotypic characteristics and the biological functions of MSCs; (2) the lack of clinical data to support the long-term safety of MSCs; (3) the need for further clarification of multiple mechanisms of MSC transplant actions in vivo; and (4) the lack of comparability of MSC transplant efficacy. Therefore, MSC-based therapies could not yet be considered a routine treatment in the clinic. Based on these, we proposed that large-scale and multi-center clinical trials of MSC-based therapies should be initiated under strict supervision. These interventions might help to establish a new clinical paradigm to turn MSC transplantation into a routine therapy for at least some diseases in the near future.
科研通智能强力驱动
Strongly Powered by AbleSci AI